Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

USFDA action on Indoco Plants: Angel Broking

Posted On: 2017-04-04 21:01:03

Views of Ms. Sarabjit Kour Nangra (VP Research- Pharma, Angel Broking):

"The USFDA had inspected Indoco Remedies manufacturing facilities (Plant II & Plant III, L-32,33,34 Verna Industrial Estate Area, Verna, Goa), from August 31st 2016 to September 4th, 2016.As an outcome of this inspection, the facility received 6 observations in Form 483, which do not pertain to data integrity. Based on the review of compliance response, USFDA accepted company's response to 4 observations. However, FDA remains concerned with respect to 2 observations, pertaining to one specific product, for which the company is contract manufacturer, for one of its customers and consequently, the company has received a warning letter from USFDA dated 27th March 2017. The company is fully committed in resolving the issue and will respond at the earliest.

As per the company, warning letter pertains to issue of leakages in the product Latanoprost, which has sales of INR 25cr p.a. Revenue exposure of plant under warning to U.S. is INR 75cr, out of the total U.S. business of INR 110cr. In terms of number of ANDAs pending from Plant III is 9, while number of ANDAs pending from Plant II is 18. While the company does not expect disruptions in supplies as of now, it expects the delay in approvals in future. AS of now the damage is very minimal to the US operations of the company and even in the worst come situation (if all the INR 75cr sales are under pressure), the impact on the net profit is expected to around 6-7%. We maintain our NEUTRAL rating on the stock."

Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.228.95 as compared to the previous close of Rs. 249.95. The total number of shares traded during the day was 226701 in over 7647 trades.

The stock hit an intraday high of Rs. 234 and intraday low of 209. The net turnover during the day was Rs. 49993818.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Company Update: KNR Constructions Ltd - BUY - TP Rs.236 - Kotak
Top Stock Picks by Arihant Capital Market
Chhota (to) MOTA ideas - CALL UPDATE: Venky's India Ltd - BUY - TP Rs.2650 - Kotak
Gabriel India Limited (GABR IN) - Shift in strategy to accelerate the growth - Initiating Coverage - CSEC Research
Banks : Some signs of life; but still weak | Sanctions made in the private corporate sector undertaken by banks/FIs - Kotak
Petroleum minister's clarification on not interfering with auto fuels pricing is a relief
Energy - OMCs (BPCL | HPCL | IOCL): A false but worrying alarm - Kotak
Company Update: Mangalore Refinery and Petrochemicals Ltd (MRPL) - BUY - TP Rs.155 - Kotak
RIL scales uncharted highs - Jio Dhan Dhana Dhan: Angel Broking
Energy-Petroleum consumption: Weakness in industrial fuels; base affects auto fuels - Kotak
Company Update: GE Shipping Company (GESCO) - BUY - TP Rs.530 - Kotak
The Pitch: BSE Ltd - BUY - TP Rs.1170 - Kotak Securities
Cess hike breather for automobile companies, removes hangover on the stocks: Angel Broking
Demerger in CESC Ltd - Kotak PCG Research
Cement:Prices remain soft - Kotak
FIEM Industries Ltd - Result Update - Kotak PCG Research
Ashok Leyland reports fastest growth after Oct-16 - Auto sales numbers analysis: Angel Broking
Bajaj Auto reports recovery in 2W exports - Auto sales numbers analysis: Angel Broking
MSIL August-17 indicates faster recovery from GST blues: Angel Broking
Dr. Reddy's Laboratories, gets a favourable district court verdict for Suboxone: Angel Broking
Company Update: FIEM Industries Ltd - BUY - TP Rs.1254 - Kotak
Sun Pharma: 1QFY2018 Result Update - Angel Broking
Cipla: 1QFY2018 Result Update - Angel Broking
Consumer Products (Cautious): 1QFY18 review - Muted quarter, but better than subdued expectations - Kotak
Result Update: Time Technoplast Ltd - ACCUMULATE - TP Rs.210 - Kotak
Result Update: PNC Infratech Ltd - ACCUMULATE - TP Rs.154 - Kotak
Result Update: Praj Industries Ltd - REDUCE - TP Rs.73 - Kotak
Result Update: Blue Star Ltd - ACCUMULATE - TP Rs.741 - Kotak
Result Update: AIA Engineering Ltd - SELL - TP Rs.1130 - Kotak
Result Update: KNR Constructions Ltd - ACCUMULATE - TP Rs.236 - Kotak
Result Update: Finolex Industries Ltd - BUY - TP Rs.712 - Kotak
HSIL Q1 FY18 Result Update Rating - HOLD - Arihant Capital Markets
CEO & MD of Infosys Resigns: Angel Broking
Indoco Remedies: 1QFY2018 Result Update - Angel Broking
Aurobindo Pharma: 1QFY2018 Result Update - Angel Broking
Insurance: Widening the base - Kotak
Banks : NIM-short term tailwinds and cyclical headwinds : Deciphering the cause of recent compression of NIM - Kotak
Jagran Prakashan Q1 FY18 Result Update Rating - HOLD - Arihant capital Markets
NCLT admits RCOM merger petition with Aircel: Angel Broking
Views on Sun Pharmaceutical Industries Limited 1QFY2018 Results: Angel Broking
Economy: RBI surplus transfer: real danger of fiscal slippage - Kotak
Views on Cadila Healthcare Ltd 1QFY2018 Results: Angel Broking
Views on Cipla Ltd 1QFY2018 Results: Angel Broking
The Pitch Report - Result Update: Balmer Lawrie Company - BUY - TP Rs.289 - Kotak
The Pitch Report - BBTC - BUY - TP Rs1130 - Kotak
Result Update: NMDC - REDUCE - TP Rs.130 - Kotak
Result Update: Mahanagar Gas Ltd - SELL - TP Rs.1006 - Kotak
Result Update: Tata Motors - BUY - TP Rs.514 - Kotak
Result Update: Gabriel India Ltd - BUY - TP Rs.190 - Kotak
Initiating Coverage: Radico Khaitan Ltd - BUY - TP Rs.200 - Kotak


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017